The Medical Advisor

Parkinson’s disease, a progressive neurodegenerative disorder, affects millions worldwide, causing debilitating symptoms like tremors, rigidity, and cognitive decline. As researchers continue to explore innovative treatments, one unexpected candidate has emerged: ivermectin, a drug traditionally used to treat parasitic infections. Recent studies have sparked curiosity about its potential neuroprotective effects, prompting questions about whether this widely available medication could offer hope for managing or even slowing the progression of Parkinson’s disease. In this article, we delve into the science behind ivermectin’s potential role in Parkinson’s treatment, examining the latest research, mechanisms of action, and what this could mean for patients seeking new therapeutic options. Can Ivermectin play a key role in treating Parkinson's Disease? Two peer-reviewed papers—one by Warnecke et al. (2020) and another by Wadsworth et al. (2024)—along with a 2021 PhD thesis by ...

Medically Reviewed by: OneDayMD Editorial Team Last Updated: April 2026 In September 2024, a first-of-its-kind protocol utilizing ivermectin, fenbendazole, and mebendazole for cancer treatment was peer-reviewed and officially published in the Journal of Orthomolecular Medicine . Led by researchers Dr. Ilyes Baghli, Dr. Pierrick Martinez, and FLCCC's Dr. Paul Marik, the protocol applies antiparasitic drugs — originally developed to combat parasites — to cancer treatment, building on emerging preclinical and clinical evidence of their anticancer properties. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondrial-Stem Cel...

Abstract Background: Stage 4 cancer — defined by metastatic spread beyond the original tumor site — has a poor prognosis with conventional treatment alone. There is growing interest in repurposed antiparasitic drugs such as ivermectin , fenbendazole , and mebendazole for potential antineoplastic effects. Preclinical research suggests mechanisms including disruption of oncogenic signaling pathways and inhibition of cancer cell proliferation and survival, but controlled clinical evidence in humans remains limited. Objective: To summarize and characterize a large compilation of anecdotal clinical case reports describing the use of ivermectin, fenbendazole, and mebendazole in individuals with Stage 4 cancers (various tumor types) and to highlight reported outcomes and therapeutic contexts. Methods: Over 320 individual case reports were aggregated from public sources — predominantly social media posts, practitioner-shared testimonials, and independently published patient narratives....